ENDRA Life Sciences Inc. (NASDAQ:NDRA) Short Interest Down 39.2% in May

ENDRA Life Sciences Inc. (NASDAQ:NDRA) saw a significant decline in short interest during the month of May. As of May 29th, there was short interest totaling 19,820 shares, a decline of 39.2% from the May 14th total of 32,603 shares. Currently, 1.7% of the company’s shares are sold short. Based on an average daily volume of 18,084 shares, the short-interest ratio is presently 1.1 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in ENDRA Life Sciences stock. Altium Capital Management LLC bought a new stake in shares of ENDRA Life Sciences Inc. (NASDAQ:NDRA) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 51,900 shares of the company’s stock, valued at approximately $235,000. ENDRA Life Sciences makes up approximately 0.9% of Altium Capital Management LLC’s investment portfolio, making the stock its 17th largest holding. Altium Capital Management LLC owned 6.92% of ENDRA Life Sciences at the end of the most recent reporting period. Hedge funds and other institutional investors own 1.19% of the company’s stock.

ENDRA Life Sciences Price Performance

ENDRA Life Sciences stock opened at $4.69 on Wednesday. The stock’s 50 day moving average is $5.11 and its 200 day moving average is $4.64. ENDRA Life Sciences has a one year low of $2.96 and a one year high of $11.96. The firm has a market cap of $5.96 million, a P/E ratio of -0.58 and a beta of -0.04.

ENDRA Life Sciences (NASDAQ:NDRA) last released its earnings results on Friday, May 15th. The company reported ($1.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.23) by $0.14. Equities analysts anticipate that ENDRA Life Sciences will post -4.11 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently commented on NDRA. Weiss Ratings reiterated a “sell (e+)” rating on shares of ENDRA Life Sciences in a research report on Monday, April 20th. Ascendiant Capital Markets decreased their price target on shares of ENDRA Life Sciences from $27.00 to $25.00 and set a “buy” rating for the company in a research report on Monday, June 1st. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, ENDRA Life Sciences presently has an average rating of “Hold” and a consensus price target of $25.00.

About ENDRA Life Sciences

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.